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We determined the incidence, risk factors and anti-
microbial susceptibility associated with Escherichia 
coli bacteraemia in England over a 24 month period. 
Case data were obtained from the national manda-
tory surveillance database, with susceptibility data 
linked from LabBase2, a voluntary national micro-
biology database. Between April 2012 and March 
2014, 66,512 E. coli bacteraemia cases were reported. 
Disease incidence increased by 6% from 60.4 per 
100,000 population in 2012–13 to 63.5 per 100,000 
population in 2013–14 (p < 0.0001). Rates of E. coli bac-
teraemia varied with patient age and sex, with 70.5% 
(46,883/66,512) of cases seen in patients aged ≥ 65 
years and 52.4% (33,969/64,846) of cases in females. 
The most common underlying cause of bacterae-
mia was infection of the genital/urinary tract (41.1%; 
27,328/66,512), of which 98.4% (26,891/27,328) were 
urinary tract infections (UTIs). The majority of cases 
(76.1%; 50,617/66,512) had positive blood cultures 
before or within two days of admission and were 
classified as community onset cases, however 15.7% 
(10,468/66,512) occurred in patients who had been 
hospitalised for over a week. Non-susceptibility to 
ciprofloxacin, third-generation cephalosporins, piper-
acillin–tazobactam, gentamicin and carbapenems 
were 18.4% (8,439/45,829), 10.4% (4,256/40,734), 
10.2% (4,694/46,186), 9.7% (4,770/49,114) and 0.2% 
(91/42,986), respectively. Antibiotic non-susceptibil-
ity was higher in hospital-onset cases than for those 
presenting from the community (e.g. ciprofloxacin 
non-susceptibility was 22.1% (2,234/10,105) for hos-
pital-onset vs 17.4% (5,920/34,069) for community-
onset cases). Interventions to reduce the incidence of 
E. coli bacteraemia will have to target the community 
setting and UTIs if substantial reductions are to be 
realised.
Introduction
Data from voluntary laboratory-based surveillance 
in England, Wales and Northern Ireland has consist-
ently shown Escherichia coli to be the most prevalent 
pathogen causing bacteraemia, with sustained annual 
increases [1]. In 2013 E. coli accounted for approxi-
mately 32% of all bacteraemia reports, an increase 
from 27% in 2009 [1]. Year-on-year increases in cases 
of bacteraemia due to E. coli have been observed 
across Europe [2]. This is reinforced by studies from 
Austria, China and the United States, which have impli-
cated E. coli as the first and second most common 
cause of community-acquired and hospital-acquired 
bloodstream infection (BSI) respectively [3-5]. A fur-
ther study from England estimated the all-cause mor-
tality rate in E. coli bacteraemia patients to be 18.2% 
between July 2011 and June 2012 [6]. In addition to a 
high mortality burden, E. coli bacteraemia has been 
associated with increases in length of hospital stay 
and difficulties with antibiotic treatment due to infec-
tions caused by resistant strains [2,7]. All of these fac-
tors increase healthcare costs and have a substantial 
clinical and economic impact [8].
In June 2011 in England, centralised reporting of cases 
of E. coli bacteraemia by National Health Service (NHS) 
hospital Trust (groups of hospitals under the same 
management) was made mandatory with the aim of 
better elucidating the increases and patterns observed 
in the voluntary surveillance programme. The present 
study is an analysis of the first two years of mandatory 
surveillance data, providing a comprehensive review of 
the current situation across the entire English NHS.
Methods
Data collection
The study period comprised two years from 1 April 
2012 to 31 March 2014, during which time all NHS acute 
Trusts (n = 167) in England reported all cases of bacte-
raemia due to E. coli to Public Health England (PHE, 
formerly the Health Protection Agency). Cases were 
reported via a web-based system originally developed 
for the mandatory surveillance of Clostridium difficile 
infection and bacteraemia caused by Staphylococcus 
aureus. Only the first blood culture positive for E. coli 
was reported, with further positive blood cultures 
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taken from the same patient within 14 days of the first 
sample regarded as the same episode of bacteraemia 
and not reported. Data items collected included the 
specimen date, patient demographics and care details 
at the time the blood culture was taken.
Patient identifiers from the mandatory E. coli dataset 
(i.e. patient name, date of birth, NHS number and hos-
pital number) were used to link with antibiotic suscep-
tibility data for the same bacteraemia case reported 
by Trust laboratories on a voluntary basis to a national 
database, LabBase2, maintained by PHE.
Data analyses
Data processing and analyses were performed using 
Stata12 (Stata Corporation, College Station, TX, US). 
E. coli population-level incidence rates were calculated 
using the Office for National Statistics (ONS) mid 2012 
and 2013 resident population estimates, based on the 
results of the 2011 census [9]. National or regional rates 
of E. coli bacteraemia were presented per 100,000 pop-
ulation. Trust-level incidence rates were presented per 
100,000 bed days, with the denominator being derived 
using 2013–14 KH03 data (organisational-level average 
daily number of occupied beds) [10]. Relevant KH03 
information for each NHS acute Trust was multiplied by 
the number of days in the study period to provide the 
total bed day denominator. Incidence risk ratios (RR) 
were expressed as risks with 95% confidence inter-
vals (CIs). Differences in categorical variables were 
assessed using a chi-squared test and considered sta-
tistically significant if two-tailed p < 0.05. Subnational 
analyses mapped cases to the four regions of England, 
and the fifteen PHE Centres (PHECs).
To compare E. coli rates between similar types of hos-
pitals, Trusts were grouped into five categories: small, 
medium or large acute Trusts, acute Specialist Trusts 
and acute Teaching Trusts. The groupings were based 
on a cross-tabulation of Estates Return Information 
Collection (ERIC) Trust categorisations and KH03 hos-
pitals bed day capacity information [10,11]. Acute 
Specialist and acute Teaching Trusts were identified 
solely using the ERIC classifications. The remain-
ing Trusts were divided into large, medium and small 
Trusts by ordering the ERIC categorisations and the 
total occupied hospital bed KH03 (2013–14) data, and 
applying a 75% inclusion of the Trusts which fell under 
the same classification in both datasets.
Cases were deemed to be hospital-onset (HO) cases if 
a patient’s specimen date was on or after the third day 
of hospital admission (where the day of admission was 
day one). Patients who had a bacteraemia detected 
before or within 2 days of admission were classified as 
community-onset (CO) [12]. Cases were categorised as 
an unknown onset if admission date was not recorded.
Antibiotic susceptibility
Following the linkage of the mandatory surveillance to 
the LabBase2 datasets, the susceptibility of E. coli to 
key antibiotic groups was evaluated, namely the beta-
lactam/beta-lactamase inhibitor combination pipera-
cillin–tazobactam, third-generation cephalosporins 
(ceftazidime and cefotaxime), a fluoroquinolone (cip-
rofloxacin), carbapenems (imipenem, meropenem 
and ertapenem) and an aminoglycoside (gentamicin). 
LabBase2 collects routinely generated antimicrobial 
susceptibility test results from hospital laborato-
ries, 95% use European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) methodology [13]. For 
the purposes of analysis, intermediate and resistant 
isolates were combined and classified as ‘non-suscep-
tible’. An isolate was considered non-susceptible to 
any of the groups above if at least one of the antibiot-
ics within the group was found to be non-susceptible.
Figure 1
Temporal incidence of Escherichia coli bacteraemia based on the voluntary and mandatory surveillance schemes, England, 
April 2000–March 2014
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Results
National and regional trends of Escherichia coli 
bacteraemia
A total of 66,512 cases of E. coli bacteraemia were 
reported between April 2012 and March 2014. There 
was a 6% increase in the annual incidence over the two 
consecutive years (32,309 cases in 2012–13, incidence 
60.4/100,000 population, 95% CI: 59.7–61.1 vs 34,203 
cases in 2013–14, incidence 63.5/100,000 population, 
95% CI: 62.8–64.2; p < 0.0001). A comparable increase 
in cases reported on a voluntary basis to LabBase2 
was also noted. A slight seasonal peak during the sec-
ond quarter (July–September) of each year was seen in 
both datasets (Figure 1).
The variation in incidence among different geographical 
areas of England (based on PHECs and regions) is shown 
in Figure 2. There were statistically significant differ-
ences in regional rates (p < 0.0001) between the highest 
rate in the North of England region (73.2/100,000 pop-
ulation/year) and the lowest in the South of England 
region (54.5/100,000 population/year), accompanied 
by a noticeable decreasing incidence gradient from the 
north to the south PHECs. When stratified by HO or CO 
of bacteraemia, both were highest in the North region 
(25.0 and 73.8/100,000 population/year, respectively), 
with 36% (5,604/15,393) of HO cases reported in the 
North region.
Disease incidence among different patient 
groups
The overall annual incidence of infection stratified 
by patient age and sex (sex data provided for 97.5%, 
64,846 cases) is shown in Figure 3. The incidence of 
E. coli bacteraemia increased with patient age for both 
females and males, with the exception of children < 1 
year of age, where the incidence was higher than in 
patients aged 1 to 64 years (Figure 3). Approximately 
a quarter (25.8%; 283/1,096) of those aged < 1 year 
were neonates aged ≤ 7 days. The overall median age 
was 75 years (interquartile range (IQR): 61–83 years), 
with 70.5% (46,883/66,512) of cases occurring in 
patients ≥ 65 years. Overall, 52.3% (33,969/64,846) 
of cases where sex was recorded were female (inci-
dence 62.3 per 100,000 female population/year) and 
47.6% (30,877/64,846) were male (incidence 58.4 per 
100,000 male population/year), which translates to 
a 7% decreased RR in males compared with females 
(p < 0.0001). Despite this, rates were higher among men 
across the majority of age groups. Rates were only 
higher among females in the following three age cat-
egories ‘1 to 14 years’ (2.9 vs 2.0 per 100,000 popu-
lation/year), ‘15 to 44 years’ (19.6 vs 6.5 per 100,000 
Figure 2
Region-specific average year rate of Escherichia coli bacteraemia in England, April 2012–March 2014 (n=66,324 patients)a
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a Wirral University Teaching Hospital NHS Foundation Trust did not report E. coli bacteraemia cases for the entire duration between April 
2012–March 2013. Hence, associated Cheshire and Merseyside PHEC average rate across the two years will not include April 2012–March 
2013 data for this acute Trust and may have caused an underestimation of the rate of infection for this PHEC.
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population/year) and ‘45 to 54 years’ (31.6 vs 27.7 
per 100,000 population/year). All three age category 
rates by sex were statistically significantly different 
(p < 0.005). Notably the female rate in the ‘15 to 44 
years’ category was threefold that of the males and 
presented the highest RR in comparison to the other 
age categories (RR: 3.0; 95% CI: 2.8–3.3). The highest 
age and sex specific rate was among men aged ≥ 85 
years, with an increased RR of 36% in males vs females 
(males: 749.2 per 100,000 population/year vs females: 
486.7 per 100,000 population/year; RR: 0.6; 95% CI: 
0.6–0.7; p < 0.0001).
Presentation of Escherichia coli bacteraemia
Seventy-four per cent (48,953/66,512) of E. coli bac-
teraemia cases were classified as CO, compared with 
23.1% (15,393/66,512) HO; 3.3%, (2,166/66,512) of 
cases were with unknown onset. Approximately 15.7% 
(10,468/66,512) were classed as late HO, i.e. occurred 
seven or more days following hospital admission.
Ninety per cent (60,135/66,512) of E. coli bacteraemia 
reports included information on patient provenance. 
Approximately three quarters of reports indicated that 
the patient was admitted from home (50,610/66,512) 
(Table 1), 46.5% (23,517/50,610) of whom were patients 
aged ≥ 75 years.
The median incidence of bacteraemia classified as 
HO was 20.5 per 100,000 bed days. The incidence of 
HO E. coli bacteraemia increased with Trust size, with 
annual median rates of 17.5, 19.7 and 22.6/100,000 
bed days for the small, medium and large acute Trusts, 
respectively. These rates were not significantly differ-
ent (Figure 4). The highest median HO rate of infection 
was seen in acute Teaching Trusts (24.6/100,000 bed 
days). The lowest median incidence (16/100,000 bed 
days) was in acute Specialist Trusts. The distribution 
of acute Specialist Trusts HO rates was wide, with the 
IQR for this Trust type entirely overlapping that of the 
small acute Trusts. There were a total of six outliers, 
the most extreme were related to ‘Specialist’ cancer 
centres (44.0 and 94.6 /100,000 bed days).
The boxes represent the 25th and 75th percentiles; the 
median line is present within the box. The lower and 
upper whiskers represent the 5th and 95th percentiles. 
Outliers are represented by dots.
The largest proportion (41.0%; 27,254/66,512) of 
reported E. coli bacteraemia cases occurred under 
the specialty of ‘general medicine’ (Table 1). ‘Surgery’ 
accounted for the second highest proportion of cases 
(12.8%; 8,506/66,512) followed by ‘care of the elderly’ 
at 8.7% (5,760/66,512).
Figure 3
Escherichia coli bacteraemia age and sex specific average 
year rates, England, April 2012–March 2014 (n=64,846 
patients)a
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a Of 66,512 cases of bacteraemia included in the study, 
information on sex was available for 64,846. Rates in the figure 
are based on the total of 64,846 patients
Table 1
Patient provenance, speciality and primary focus of Escherichia coli bacteraemia, England, April 2012–March 2014 
(n = 66,512 patients)a
Patient provenance n (%) Specialty n (%) Primary focus of infection n (%)
Home 50,610 (76.1) General medicine 27,254 (41.0) Genital/urinary tract 27,328 (41.1)
Nursing/residential home 5,352 (8.0) Otherb 9,525 (14.3) Unknown 11,971 (18.0)
Not known 2,051 (3.1) Surgery 8,506 (12.8) Hepatobiliary 7,611 (11.4)
Hospital (UK or abroad, incl. private) 1,380 (2.1) Care of the elderly 5,760 (8.7) Gastrointestinal (not hepatobiliary) 3,493 (5.3)
Otherc 469 (0.7) A and E 5,381 (8.1) Respiratory tract 2,065 (3.1)
PCT Hospital 156 (0.2) Urology related 2,005 (3.0) Otherd 1,932 (2.9)
Non-UK resident 117 (0.2) Oncology 1,644 (2.5) Indwelling intravascular device 828 (1.2)
Blank 6,377 (9.6)
Paediatrics 1,351 (2.0) Skin/soft tissue 610 (0.9)
Not known 424 (0.6)
Blank 10,674 (16.0)
Blank 4,662 (7.0)
A and E: Accident and Emergency; Incl.: including; PCT: Primary Care Trust; UK: United Kingdom.
a Of 66,512 cases of bacteraemia included in the study, information on patient provenance was available for 60,135 cases, on speciality for 
61,850 and on the underlying primary focus for 55,838. Percentages in the table are based on the total of 66,512 patients.
b Specialities which were not commonly reported were grouped as ‘other’.
c Including temporary accommodation and penal establishment.
d Including: no clinical signs, bone and joint, central nervous system.
5www.eurosurveillance.org
The underlying primary focus of the bacteraemia was 
reported in 84.0% (55,838/66,512) of cases. ‘Genital/
urinary tract’ was thought to be the source for just 
under half of case (41.1%; 27,328/66,512); 98.4% 
(26,891/27,328) of these were urinary tract infections 
(UTIs). For 18.0% (11,971/66,512) of cases the primary 
focus was unknown. Genital/urinary tract source of 
infections were associated with 44.0% (21,526/48,953) 
of patients with a CO E. coli bacteraemia and 34.1% 
(5,247/15,393) of patients with HO.
E. coli bacteraemia with a urinary primary focus of 
infection were associated with a higher proportion of 
females than males (56.0% 15,058/26,891 vs 42.0% 
11,274/26,891 respectively). Notably, the disparities 
according to sex were most evident between the three 
age groups which spanned 1 to 54 years of age (1–14 
years: females 67.4% (62/92) vs males 29.3% (27/92), 
p < 0.0001; 15–44 years: females 82.8% (2,094/2,528) 
vs males 14.7% (371/2,528), p < 0.006; 45–54 years: 
females 62.8% (1,050/1,672) vs males 34.8% 
(582/1,672), p < 0.0009).
Where the primary focus of infection was given as UTI, 
69.5% (5,255/7,559) of the records with a response 
indicated the presence of a urinary catheter. However, 
this field was poorly completed and not representative, 
with 72% of cases missing this information.
Antibiotic susceptibility
Eighty-two per cent (54,301/66,512) of E. coli bac-
teraemia records from the mandatory surveillance 
were successfully linked to antibiotic susceptibility 
data. Non-susceptibility was highest for ciprofloxacin 
(18.4%; 8,439/45,829) and lowest for the carbapenems 
(0.2%; 91/42,986) (Table 2).
Although the proportions of isolates non-susceptible 
to the various antibiotics were similar between the two 
successive years, there was an increase in the number 
of isolates non-susceptible to these antibiotics. In par-
ticular, piperacillin–tazobactam non-susceptible cases 
increased by 10.9% (2,226 cases in 2012–13; 2,468 
cases in 2013–14).
Similar levels of non-susceptibility were observed at 
the regional level compared with nationally, i.e. non-
susceptibility to ciprofloxacin was the highest and 
carbapenem non-susceptibility was the lowest across 
all the PHECs. Although the ranking was similar there 
were nonetheless regional variations in the propor-
tions of E. coli that were non-susceptible to antibiotics. 
Unlike the North–South variation seen with the inci-
dence of E. coli bacteraemia, non-susceptibility was 
generally highest in the London region. The London 
PHEC had the highest proportion of non-susceptibility 
to ciprofloxacin (25.4%; 1,742/6,868), piperacillin–
tazobactam (12.8%; 893/6,977), gentamicin (15.2%; 
1,098/7,216), and one of the highest to third-genera-
tion cephalosporins (14.9%; 951/6,400). These were 
significantly different (p < 0.0001) to the lowest levels 
of non-susceptibility seen in the North East PHEC (cip-
rofloxacin 13.4% 434/3,237; third-generation cephalo-
sporins 6.3% 201/3,187; gentamicin 5.5% 183/3,342). 
Yorkshire and Humber, and Thames Valley PHECs were 
excluded from the analysis as only 61% and 56% of 
cases were successfully linked.
When stratified by onset, non-susceptibility to all study 
antibiotics was higher in HO cases (Table 2). Non-
susceptibility in HO cases have marginally decreased 
over the two study years, particularly for ciprofloxa-
cin and third-generation cephalosporins (10% and 11% 
decrease), whereas the CO have increased; 10% and 
9% rise in non-susceptibility to third-generation ceph-
alosporins and piperacillin–tazobactam, respectively 
(p < 0.05). Piperacillin–tazobactam presented the larg-
est disparity between HO and CO, with nearly twofold 
difference in the proportion of isolates showing non-
susceptibility in HO cases (15.1%, 1,562/10,363) com-
pared with the CO (8.7%, 2,986/34,175).
There were statistically significant differences in the 
proportion of antibiotic non-susceptibility in males 
compared with females for all antibiotics apart from 
the carbapenems, particularly for ciprofloxacin (males: 
20.9% 4,433/21,236; female: 16.2%, 3,783/23,320; 
p < 0.0001). Within the 15 to 44 year age group, the 
proportion of males with E. coli not susceptible to cip-
rofloxacin was significantly higher than the propor-
tion for females (males: 20% 183/899; females: 11% 
298/2,812; p < 0.0001). Non-susceptibility for each 
antibiotic class, apart from carbapenems, increased 
with age, with the highest non-susceptibilities seen in 
infections in patients aged ≥ 65 years.
Figure 4
Box-and-whisker plots showing hospital-onset Escherichia 
coli bacteraemia annual rates, by Trust size and type, 
England, April 2012–March 2014
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Discussion
The linkage of E. coli bacteraemia cases, reported by 
Trusts as part of a mandatory surveillance scheme to 
susceptibility data reported by laboratories on a volun-
tary basis, has enabled a comprehensive analysis that 
gives insight into the national epidemiology and bur-
den of E. coli bacteraemia across England. Mandatory 
surveillance of E. coli bacteraemia was implemented in 
June 2011 hence long-term trends over time have not 
been fully established; however the rise in incidence 
across the two years has mirrored the year-on-year 
increase in incidence seen in the voluntary surveil-
lance dataset. The results presented here, along with 
an emerging body of evidence, suggest that there is 
seasonal variation in E. coli bacteraemia rates, with a 
peak during the summer [14,15].
Analysis of geographical variation in infection rates 
showed a North–South divide, with the South of 
England having a lower and the North a higher E. coli 
bacteraemia rate than the average for England. Various 
other regional data resonate with this division, with 
the North having higher health inequalities and poorer 
health outcomes [16]. There were differences in the 
proportion of HO rates, suggesting that the geographi-
cal heterogeneity may be associated with provision of 
healthcare.
E. coli bacteraemia incidence rates generally increased 
with age, across both sexes, with a high proportion 
of E. coli bacteraemia occurring in patients aged ≥ 65 
years (85.5%). We identified a larger incidence among 
patients aged ≤ 1 year compared with those a few years 
Table 2
Number and percentage of non-susceptible Escherichia coli bacteraemia strains to selected antibiotics, England, April 
2012–March 2014
Criteria Ciprofloxacin Third generation cephalosporinsa
Piperacillin–
Tazobactam Gentamicin Carbapenems
b
2012–14
Number tested 45,829 40,734 46,186 49,114 42,986
Number of 
non-susceptible 8,439 4,256 4,694 4,770 91
Non-susceptible (%) 18.4 10.4 10.2 9.7 0.21
Age group 
in years  
n/Nc (%)
< 1 56/673 (8.3) 34/661 (5.1) 32/671 (4.8) 55/749 (7.3) 0/615 (0.00) 
1–14 53/250 (21.2) 40/229 (17.5) 35/250 (14.0) 37/263 (14.1) 5/202 (2.48)
15–44 493/3,821 (12.9) 268/3,380 (7.9) 311/3,842 (8.1) 333/4,105 (8.1) 10/3,521 (0.28)
45–54 546/3,130 (17.4) 264/2,772 (9.5) 284/3,162 (9.0) 336/3,309 (10.2) 11/2,940 (0.37)
55–64 1,027/5,376 (19.1) 501/4,779 (10.5) 554/5,391 (10.3) 551/5,742 (9.6) 12/5,024 (0.24)
65–74 1,844/9,362 (19.7) 887/8,302 (10.7) 941/9,439 (10.0) 1,006/9,997 (10.1) 13/8,816 (0.15)
75–84 2,379/13,003 (18.3) 1,238/11,511 (10.8) 1,404/13,101 (10.7) 1,358/13,964 (9.7) 23/12,215 (0.19)
>84 2,041/10,214 (20.0) 1,024/9,100 (11.3) 1,133/10,330 (11.0) 1,094/10,985 (10.0) 17/9,653 (0.18)
Sex  
n/Nc (%)
Female 3,783/23,320 (16.2) 2,013/20,685 (9.7) 2,235/23,462 (9.5) 2,252/25,025 (9.0) 40/21,817 (0.18)
Male 4,433/21,236 (20.9) 2,102/18,845 (11.2) 2,322/21,443 (10.8) 2,403/22,749 (10.6) 51/19,948 (0.26)
Unknown 223/1,273 (17.5) 141/1,204 (11.7) 137/1,281 (10.7) 115/1,340 (8.6) 0/1,221 (0.00)
Focus  
n/Nc (%)
Genital/urinary tract 3,915/19,543 (20.0) 1,952/16,595 (11.8) 1,991/19,161 (10.4) 2,387/20,566(11.6) 34/18,086 (0.19)
Indwelling 
intravascular device 122/529 (23.1) 57/471 (12.1) 73/534 (13.7) 78/553 (14.1) 2/477 (0.42)
Skin/soft tissue 86/430 (20.0) 43/361 (11.9) 50/436 (11.5) 44/450 (9.8) 2/394 (0.51)
Onset 
setting  
n/Nc (%)
Hospital 2,234/10,105 (22.1) 1,306/9,099 (14.4) 1,562/10,363 (15.1) 1,469/10,901 (13.5) 33/9,585 (0.34)
Community 5,920/34,069 (17.4) 2,802/30,072 (9.3) 2,986/34,175 (8.7) 3,154/36,497(8.6) 56/31,816 (0.18)
Trust 
category  
n/Nc (%)
Large acute 584/2,877 (20.3) 313/2,660 (11.8) 485/3,216 (15.1) 402/3,394 (11.8) 6/2,959 (0.20)
Medium acute 489/2,417 (20.2) 280/2,040 (13.7) 307/2,352 (13.1) 320/2,563 (12.5) 7/2,331 (0.30)
Small acute 270/1,179 (22.9) 184/1,051 (17.5) 176/1,163 (15.1) 184/1,314 (14.0) 4/1,094 (0.37)
Acute Teaching 808/3,261 (24.8) 472/3,003 (15.7) 548/3,258 (16.8) 503/3,236 (15.5) 15/2,867 (0.52)
Acute Specialist NAd NAd NAd NAd NAd
NA: not applicable.
a Third-generation cephalosporins were represented by ceftazidime and cefotaxime. Isolates non-susceptible to any of these two antibiotics 
were considered as non-susceptible to third generation cephalosporins.
b Carbapenems were represented by imipenem, meropenem and ertapenem. Isolates non-susceptible to any of these three antibiotics 
were considered as non-susceptible to carbapenems. The proportions of isolates that are non-susceptibile to carbapenems in England is 
currently very low. To visualise differences between the groups (age/sex/focus/onset setting/trust type), the proportions of isolates that 
are non-susceptible to this particular antibiotic group are presented with a two decimal point precision.
c The numbers supporting the percentages presented are provided, whereby the denominators represent the total number of isolates tested 
per category within each group considered (age/sex/focus/onset setting/trust type).
d Only 52% of cases occurring in Specialist Trust were successfully linked to antibiotic susceptibility data; as a result of this further analysis 
was not performed on this Trust group.
7www.eurosurveillance.org
older. These findings are in agreement with previous 
studies [5,16-20], and are related to the vulnerability 
of these groups to infection, with the very young being 
immunologically naive and older age patients having 
progressively deteriorating immune systems, increas-
ing comorbidities and invasive healthcare procedures 
[21,22]. There was increasing infection with decreasing 
neonatal age, particularly in neonates aged less than 
a week, indicative of vertical transmission events. E. 
coli infections in preterm neonates, along with group 
B streptococcal infection, contribute a substantial bur-
den of disease in this patient group [23].
Evident sex differences in the distribution of E. coli 
bacteraemia by age were present; rates were higher 
in females between 1 and 54 years of age and greater 
in males in the older age groups (> 54), this is consist-
ent with previous findings [17,18]. E. coli bacteraemia 
frequently occurs as a complication following a UTI. 
Indeed, the greater bacteraemia rate among females 
were likely due to a higher proportion of UTIs occurring 
among females aged between 1 and 54 years. Females 
have a higher predisposition for UTIs compared with 
males due to their urethras being shorter and in closer 
proximity to the rectum [24].
The most common source of infection leading to E. coli 
bacteraemia was the genital/urinary tract. This was 
associated with increasing age, with older patients 
becoming more susceptible to UTIs perhaps due to 
increasing urological co-morbidities and the increased 
use of catheters. Older males are more prone to pros-
tate problems which can lead to urinary retention and 
UTIs; the performance of prostate biopsies is an addi-
tional risk factor for bacteraemia in males aged over 54 
years [17]. 
A large percentage of cases were reported with an 
‘unknown’ focus of infection (18.0%). Treatment of such 
infections may prove problematic, as without identifi-
cation of the source it is difficult to target interventions 
that will remove or nullify it. An unresolved infection 
source risks the repeated seeding of the bacteria into 
the blood, leading to repeated episodes and prolonged 
patient exposure to antibiotics, increasing the risk of 
selecting for antibiotic resistant strains.
The study indicates that approximately three-quarters 
of E. coli bacteraemias were of CO. Other studies have 
also found higher rates in community-acquired bac-
teraemia [20,25]. Approximately 16% were late-HO 
patients and had been under the care of the Trust for 
a week or more before their bacteraemia establishing, 
thus they represent cases likely to be hospital acquired 
and therefore the most amenable to prevention via 
hospital based infection control measures.
A limitation which warrants further investigation is 
the need to differentiate CO infections that are com-
munity-acquired versus those that have an associa-
tion with prior healthcare i.e. healthcare-associated 
infections. The simplistic categorisation of ‘pre-day 2 
of hospital admission’ cases as ‘community’ fails to 
account for infections acquired as a result of outpatient 
care, or those occurring immediately after discharge 
[12,18,25,26]. A proportion of the ‘community’ cases 
observed in the study may, in part, be the result of this 
lack of precision. There was a high proportion of cases 
reported to have been admitted from home. These 
findings reflect the complexity of procedures which 
are now being delivered in the community or where the 
patient has been discharged from hospital to continue 
convalescing at home.
Larger acute Trusts were associated with a higher rate 
of infection. A larger Trust has a corresponding larger 
pool of susceptible individuals, immunocompromised 
patients, higher patient per nurse ratio, wider use of 
antimicrobials which could lead to selection pressures, 
and greater challenges in maintaining infection control 
measures [27,28]. The highest median HO rate of infec-
tion was seen in acute Teaching Trusts, these Trusts 
generally have more complex, tertiary care patients 
than general acute Trusts [29]. The acute Specialist 
Trusts had the highest variance, the outliers seen in 
this group were in two specialist cancer Trusts. Most 
cancer treatments affect a patient’s susceptibility to 
infection [30]. The use of invasive devices (e.g. intrave-
nous lines), prior exposure to antimicrobial therapy and 
multiple hospitalisations would increase a patient’s 
risk of acquiring a bacteraemia [31]. The heterogeneity 
of case mix within and across Trust types, particularly 
Specialist Trusts, and the lack of statistical differences 
limits our ability to determine whether the findings 
were genuine or due to artefact.
The proportions of isolates non-susceptible to the anti-
biotics tested did not vary greatly between the two 
years. However, while the stability of resistance in E. 
coli over recent years has been highlighted in the lit-
erature [20,32], the increased incidence of bacteraemia 
caused by E. coli, means that the burden of resistant 
infections has nonetheless continued to rise [33].
Non-susceptibility to carbapenems remains low in 
England. The isolates non-susceptible to carbapen-
ems were more closely associated with HO cases, than 
for any of the other antibiotic classes. Carbapenems 
are often considered as ‘last-line’ antibiotics for 
Enterobacteriaceae, as carbapenem-resistant isolates 
often exhibit resistance to multiple antibiotic classes, 
severely limiting the number of effective therapies 
available. Although carbapenems account for a minor-
ity of total antibiotic consumption, we have seen the 
consumption of carbapenems increase by 31.3% in 
England between 2010 and 2013 [33].
Non-susceptibility to ciprofloxacin was higher than 
for any of the other antimicrobials (18.4%). Resistance 
to a fluoroquinolone is often associated with resist-
ance to other antibiotics frequently indicated for UTIs 
(e.g. trimethoprim), with ciprofloxacin itself currently 
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stated as the first line treatment for complicated UTIs 
[13]. English prescribing guidance over the past dec-
ade has reduced the recommended duration of tri-
methoprim treatment for uncomplicated cystitis and 
shifted to nitrofurantoin as the first-line option [34]. 
Previous suboptimal antibiotic consumption could have 
impacted on an increase in recurrent UTIs, propensity 
of bacteraemia and non-susceptibility [34].
During the last decade in England, there has been 
a prescribing shift away from fluoroquinolones and 
third-generation cephalosporins, towards higher use 
of beta-lactamase/inhibitor combinations and carbap-
enems; this may in part explain the rise in piperacillin–
tazobactam non-susceptibility, however laboratories 
changing over from Clinical and Laboratory Standards 
Institute (CLSI) to EUCAST breakpoint and methods, 
could also explain the increases [13,33].
Unlike the geographical variation seen with E. coli inci-
dence, non-susceptibility was generally highest in the 
London region. As the susceptibility data are collected 
by voluntary reporting, it could be that variations 
reflect differences in reporting. However this finding is 
in accordance with the higher prevalence of antimicro-
bial consumption reported in London [33].
Antibiotic non-susceptibility was generally higher in 
the HO cases, notably piperacillin–tazobactam. This is 
most probably due to greater selection pressures in the 
hospital environment. Piperacillin–tazobactam, is also 
predominantly used in the hospital setting [33]. Across 
the two years there has been a marginal increase in 
antibiotic non-susceptibility in CO cases. Recent stud-
ies show a rise in community prescribing, particularly 
in general practices [33].
E. coli bacteraemia in males were more likely to be 
non-susceptible than in females, agreeing with obser-
vations from other studies [32,35]. Since the propor-
tion of non-susceptible E. coli is higher with older age 
(≥ 65 years) and older age categories are known to have 
higher rates of bacteraemia in males compared with 
females, it is likely that a higher proportion of males 
have more complicated infections, frequently with hos-
pital strains, are exposed to more antimicrobial ther-
apy, which increases selection pressure and results in 
higher proportions of non-susceptibility.
Increases in rates of E. coli bacteraemia are multi-
factorial and may in part be explained by an ageing 
population, increased international travel and con-
sumption of antibiotics. The present study suggests 
that interventions targeting the source of infection, 
particularly UTIs, may be effective in reducing rates. 
Reduction in prescribing of broad-spectrum antibi-
otics also has the potential to decrease the rates of 
bacteraemia due to resistant bacterial strains. Further 
investigation into the true onset of bacteraemia would 
be beneficial. Similarly, research into the geographical 
variations observed would be advantageous. Ongoing 
surveillance will assist with the majority of the above 
and will help identify and assess potential interven-
tions to ultimately reduce the emerging threat of anti-
microbial resistance.
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